Harms Reporting in Randomized Controlled Trials of Interventions Aimed at Modifying Microbiota RESPONSE

被引：3

作者：

Bafeta, Aida ^{[1
,2
]}

Koh, Mitsuki ^{[3
]}

Riveros, Carolina ^{[1
,2
]}

Ravaud, Philippe ^{[1
,2
,4
]}

机构：

[1] INSERM, U1153, Paris, France

[2] Univ Paris 05, Sorbonne Paris Cite, Paris, France

[3] Columbia Univ, New York, NY USA

[4] French Cochrane Ctr, Paris, France

来源：

ANNALS OF INTERNAL MEDICINE | 2019年 / 170卷 / 02期

关键词：

SAFETY;

D O I：

10.7326/L18-0562

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

引用

页码：143 / 144

页数：2

共 4 条

[1]

Risk and Safety of Probiotics [J].

Doron, Shira ;

Snydman, David R. .

CLINICAL INFECTIOUS DISEASES, 2015, 60 :S129-S134

[2]

Adverse Events in Randomized Trials Neglected, Restricted, Distorted, and Silenced [J].

Ioannidis, John P. A. .

ARCHIVES OF INTERNAL MEDICINE, 2009, 169 (19) :1737-1739

[3]

Safety assessment of probiotics for human use [J].

Sanders, Mary Ellen ;

Akkermans, Louis M. A. ;

Haller, Dirk ;

Hammerman, Cathy ;

Heimbach, James ;

Hoermannsperger, Gabriele ;

Huys, Geert ;

Levy, Dan D. ;

Lutgendorff, Femke ;

Mack, David ;

Phothirath, Phoukham ;

Solano-Aguilar, Gloria ;

Vaughan, Elaine .

GUT MICROBES, 2010, 1 (03) :164-185

[4]

von Wright A, 2005, CURR PHARM DESIGN, V11, P17

← 1 →